Survival (time to event) data: median survival times | The BMJ
Cancers | Free Full-Text | Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience
NEJM on X: "Nivolumab increases median overall survival by 5.4 months in adv renal cell cancer. #ECC2015 http://t.co/9DSZcnbnAs http://t.co/22qcFuEfzN" / X
TTFields in Unresectable MPM: STELLAR Results in Practice - ILCN.org (ILCN/WCLC)
MARGENZA® Clinical Results
Median Survival Time - an overview | ScienceDirect Topics
VYXEOS® Efficacy - Phase 3 Trial Data vs 7+3 | VYXEOS® (daunorubicin and cytarabine)
Kaplan–Meier survival curves. (A) Median overall survival was... | Download Scientific Diagram
Metastasectomy and Targeted Therapy for Patients With Spinal Metastases of Renal Cell Carcinoma | International Journal of Spine Surgery
Prognostic Factors for Gastric Cancer Patients With One Stage IV Factor who Underwent Conversion Surgery | Anticancer Research
Efficacy Results | ONIVYDE® (irinotecan liposome injection) | HCP | Onivyde
Efficacy Data | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Survival curves. (A) Overall survival (median 18.2 months). (B) PS of... | Download Scientific Diagram
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Frontiers | Treatment and survival analysis for 40-year SEER data on upper esophageal cancer
GraphPad Prism 10 Statistics Guide - Determining the median followup time
Early Clinical Data Suggests Nearly 2X Prolonged Median Survival for Inoperable, Locally Advanced Pancreatic Cancer with
survival - Time to event analysis - median (IQR) is <75% experience event - Cross Validated
Median overall survival according to changes in CA 19-9 | Open-i
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis | Leukemia
